GSK
GSK
GSK
LSE
1301.00
GBX
-3.88%
Dividends
Payment date
9 Jan 2025
Ex-date
14 Nov 2024
Amount
0.15 GBP
About
GSK plc is a global biopharma company. The Company’s segments include Commercial Operations and Research and Development. It develops cancer medicines for patients, including ovarian cancer, endometrial cancer, and multiple myeloma. Its product areas include vaccines, specialty medicines, and general medicine.
It is also focused on addressing the unmet treatment needs of patients with respiratory and inflammatory conditions. Its vaccine portfolio includes over 20 vaccines that help to protect people from a range of diseases and infections, including meningitis, shingles and flu, among others. Its specialty medicines are also engaged in developing medicines for respiratory disease and HIV.
Its general medicines include inhaled medicines for asthma and chronic obstructive pulmonary disease, antibiotics, and medicines for skin diseases. It is advancing oligonucleotide therapeutics in chronic hepatitis B and steatotic liver disease as well as other therapeutic areas beyond liver disease..
Financials Amount (in millions)
Income statement
Balance sheet
Cash flow
Ratios
| Price and Volume | |
|---|---|
| Volume | |
| Ten Day Average Volume | 6.2M |
| Three Month Average Volume | 157.6M |
| High Low | |
| Fifty-Two Week High | 18.235 GBX |
| Fifty-Two Week Low | 13.596 GBX |
| Fifty-Two Week High Date | 16 May 2024 |
| Fifty-Two Week Low Date | 06 Sep 2023 |
| Price and Volume | |
| Current Price | 16.505 GBX |
| Beta | 1 |
| Relative Price Change | |
| Four Week Relative Price Change | 2.26% |
| Thirteen Week Relative Price Change | 2.14% |
| Twenty-Six Week Relative Price Change | -9.56% |
| Fifty-Two Week Relative Price Change | 5.97% |
| Year-to-Date Relative Price Change | 5.45% |
| Price Change | |
| One Day Price Change | -0.39% |
| Thirteen Week Price Change | 3.29% |
| Twenty-Six Week Price Change | -1.04% |
| Five Day Price Change | 3.00% |
| Fifty-Two Week Price Change | 18.95% |
| Year-to-Date Price Change | 13.81% |
| Month-to-Date Price Change | -0.39% |
| Per Share Data | |
|---|---|
| Book Value | |
| Book Value Per Share (Last Fiscal Year) | 3.29047 GBX |
| Book Value Per Share (Most Recent Quarter) | 3.52341 GBX |
| Tangible Book Value Per Share (Last Fiscal Year) | -2.02946 GBX |
| Tangible Book Value Per Share (Most Recent Quarter) | -1.97622 GBX |
| EBITD | |
| EBITD Per Share (Trailing Twelve Months) | 2.56021 GBX |
| Revenue | |
| Revenue Per Share (Last Fiscal Year) | 7.37728 GBX |
| Revenue Per Share (Trailing Twelve Months) | 7.63618 GBX |
| Dividend | |
| Dividend Per Share (Last Fiscal Year) | 0.58 GBX |
| Dividend Per Share (Trailing Twelve Months) | 0.6 GBX |
| Dividend Per Share (5 Year) | 0.8385 GBX |
| Earnings Per Share | |
| Excluding Extraordinary Items (Last Fiscal Year) | 1.19874 GBX |
| Excluding Extraordinary Items (Trailing Twelve Months) | 0.97955 GBX |
| Normalized (Last Fiscal Year) | 1.40306 GBX |
| Basic Excluding Extraordinary Items (Last Fiscal Year) | 1.21619 GBX |
| Basic Excluding Extraordinary Items (Trailing Twelve Months) | 0.99186 GBX |
| Including Extraordinary Items (Last Fiscal Year) | 1.19874 GBX |
| Including Extraordinary Items (Trailing Twelve Months) | 0.97955 GBX |
| Cash | |
| Cash Per Share (Last Fiscal Year) | 1.23069 GBX |
| Cash Per Share (Most Recent Quarter) | 0.73131 GBX |
| Cash Flow Per Share (Last Fiscal Year) | 1.84919 GBX |
| Cash Flow Per Share (Trailing Twelve Months) | 1.62869 GBX |
| Free Cash Flow Per Share (Trailing Twelve Months) | 0.68941 GBX |
| Margins | |
|---|---|
| Cash Flow Revenue | |
| Cash Flow Revenue (5 Year) | 6 |
| Cash Flow Revenue (Trailing Twelve Months) | 9 |
| Pretax Margin | |
| Pretax Margin (Trailing Twelve Months) | 15.96% |
| Pretax Margin (Last Fiscal Year) | 19.99% |
| Pretax Margin (5 Year) | 18.73% |
| Gross Margin | |
| Gross Margin (Last Fiscal Year) | 72.42% |
| Gross Margin (Trailing Twelve Months) | 72.84% |
| Gross Margin (5 Year) | 70.29% |
| Operating Margin | |
| Operating Margin (Last Fiscal Year) | 22.24% |
| Operating Margin (Trailing Twelve Months) | 17.99% |
| Operating Margin (5 Year) | 21.37% |
| Net Profit Margin | |
| Net Profit Margin (Last Fiscal Year) | 17.50% |
| Net Profit Margin (Trailing Twelve Months) | 13.73% |
| Net Profit Margin (5 Year) | 16.93% |
| Growth | |
|---|---|
| Book Value | |
| Book Value Per Share (5 Year) | 24.34% |
| Tangible Book Value (5 Year) | -99,999.99% |
| Free Operating Cash Flow | |
| Free Operating Cash Flow (5 Year) | -4.20% |
| Revenue | |
| Revenue Change MRQ vs 1 Year Ago | 9.84% |
| Revenue Growth (3 Year) | -0.32% |
| Revenue Change (Trailing Twelve Months) | 7.20% |
| Revenue Per Share Growth | -0.98% |
| Revenue Growth (5 Year) | 7.59% |
| Capital Spending Debt | |
| Capital Spending (5 Year) | 5.47% |
| Total Debt (5 Year) | -7.12% |
| Dividends | |
| Dividend Growth (3 Year) | -16.60% |
| Earnings Per Share | |
| EPS Change MRQ vs 1 Year Ago | -28.28% |
| EPS Change (Trailing Twelve Months) | -25.23% |
| EPS Growth (3 Year) | 6.39% |
| EPS Growth (5 Year) | 2.67% |
| EBITDA | |
| EBITDA (5 Year) | 0.33% |
| EBITDA (5 Year Interim) | -1.56% |
| Net Profit Margin | |
| Net Profit Margin Growth (5 Year) | 6.59% |
| Valuation | |
|---|---|
| Total Price to Book | |
| Price to Tangible Book (Last Fiscal Year) | -100,000 |
| Price to Tangible Book (Most Recent Quarter) | -100,000 |
| Price to Free Cash Flow | |
| Price to Free Cash Per Share (Last Fiscal Year) | 31 |
| Price to Free Cash Per Share (Trailing Twelve Months) | 24 |
| Net Debt | |
| Net Debt (Most Recent Quarter) | 14.0B |
| Net Debt (Last Fiscal Year) | 13.0B |
| Price to Sales | |
| Price to Sales (Last Fiscal Year) | 2 |
| Price to Sales (Trailing Twelve Months) | 2 |
| Price to Earnings | |
| PE Excluding Extraordinary Items (Last Fiscal Year) | 17 |
| PE Normalized (Last Fiscal Year) | 12 |
| PE Basic Excluding Extraordinary Items (Trailing Twelve Months) | 15 |
| PE Excluding Extraordinary Items High (Trailing Twelve Months) | 24 |
| PE Excluding Extraordinary Items Low (Trailing Twelve Months) | 9 |
| PE Including Extraordinary Items (Trailing Twelve Months) | 17 |
| Dividends | |
| Dividend Yield (5 Year) | 5.47% |
| Dividend Yield | 3.64% |
| Current Dividend Yield | 3.64% |
| Price to Book | |
| Price to Book (Last Fiscal Year) | 5 |
| Price to Book (Most Recent Quarter) | 5 |
| Financial Strength | |
|---|---|
| Debt to Equity | |
| Long Term Debt to Equity (Last Fiscal Year) | 114 |
| Long Term Debt to Equity (Most Recent Quarter) | 94 |
| Payout Ratio | |
| Payout Ratio (Last Fiscal Year) | 47.73% |
| Payout Ratio (Trailing Twelve Months) | 60.53% |
| Quick Ratio | |
| Quick Ratio (Last Fiscal Year) | 1 |
| Quick Ratio (Most Recent Quarter) | 1 |
| Enterprise Value | |
| Current Enterprise Value to Free Cash Flow (Last Fiscal Year) | 27 |
| Current Enterprise Value to Free Cash Flow (Trailing Twelve Months) | 40 |
| Current Ratio | |
| Current Ratio (Last Fiscal Year) | 1 |
| Current Ratio (Most Recent Quarter) | 1 |
| Free Cash Flow | |
| Free Cash Flow (Last Fiscal Year) | 2.2B |
| Free Cash Flow (Trailing Twelve Months) | 2.8B |
| Net Interest Coverage | |
| Net Interest Coverage (Last Fiscal Year) | 7 |
| Net Interest Coverage (Trailing Twelve Months) | 13 |
| Total Debt to Equity | |
| Total Debt to Equity (Last Fiscal Year) | 135 |
| Total Debt to Equity (Most Recent Quarter) | 118 |
| Management Effectiveness | |
|---|---|
| Return on Assets | |
| Return on Assets (Last Fiscal Year) | 8.91% |
| Return on Assets (Trailing Twelve Months) | 7.35% |
| Return on Assets (5 Year) | 6.74% |
| Return on Equity | |
| Return on Equity (Last Fiscal Year) | 41.16% |
| Return on Equity (Trailing Twelve Months) | 29.80% |
| Return on Equity (5 Year) | 34.87% |
| Return on Investment | |
| Return on Investment (Last Fiscal Year) | 13.91% |
| Return on Investment (Trailing Twelve Months) | 11.33% |
| Return on Investment (5 Year) | 10.71% |